Literature DB >> 19116630

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow.

Malisha R Johnson1, Srdan Verstovsek, Jeffrey L Jorgensen, T Manshouri, Raja Luthra, Dan M Jones, Carlos E Bueso-Ramos, L Jeffrey Medeiros, Yang O Huh.   

Abstract

In the World Health Organization classification, one major and four minor criteria are specified for the diagnosis of systemic mastocytosis. We report our experience using these criteria to diagnose systemic mastocytosis involving bone marrow. A total of 59 patients with clinically suspected systemic mastocytosis underwent comprehensive bone marrow examination, including immunophenotyping by immunohistochemistry and/or flow cytometry and molecular studies for KIT exon 17 mutations. Serum tryptase levels were also assessed. Of these 59, 53 (90%) patients met the diagnostic criteria for systemic mastocytosis. In these patients, multifocal dense infiltrates of mast cells, the major criterion, was observed in 36 (68%) patients. Atypical mast cell morphology was observed in 53 (100%), an aberrant immunophenotype was identified in 50 of 52 (96%), KIT mutation was present in 33 of 44 (75%), and an elevated serum tryptase (>20 ng/ml) was detected in 44 of 52 (85%). In the six patients in which bone marrow examination could not confirm systemic mastocytosis, one had systemic mastocytosis involving spleen, one patient had chronic idiopathic myelofibrosis, and four had no specific diagnosis, but systemic mastocytosis was still considered most likely. Of these six patients, atypical mast cell morphology was identified in five, aberrant immunophenotype in five, KIT mutation in two, and elevated serum tryptase in two. None of these cases met the major criteria. We conclude that the World Health Organization criteria are useful for the diagnosis of systemic mastocytosis in bone marrow specimens. The results also show the relative values of traditional morphologic criteria (ie, major criterion) and the results of ancillary testing (ie, minor criteria). However, as illustrated by the case of splenic systemic mastocytosis as well as the patient with chronic idiopathic myelofibrosis, the current World Health Organization system is neither completely sensitive nor specific for systemic mastocytosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116630     DOI: 10.1038/modpathol.2008.141

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

Review 1.  [Systemic mastocytosis--definition of an internal disease].

Authors:  Jürgen Homann; Ulrich W Kolck; Andreas Ehnes; Thomas Frieling; Martin Raithel; Gerhard J Molderings
Journal:  Med Klin (Munich)       Date:  2010-09-08

2.  Re: Mastocytosis--a disease of the hematopoietic stem cell. Problematic criteria.

Authors:  Jürgen Homann; Ulrich Kolck; Gerhard J Molderings
Journal:  Dtsch Arztebl Int       Date:  2009-03-06       Impact factor: 5.594

3.  Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia.

Authors:  E J Vannorsdall; J A Collins; Q C Chen; G Sarai; M R Baer
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

Review 4.  Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.

Authors:  Alfonso Quintás-Cardama; Nitin Jain; Srdan Verstovsek
Journal:  Cancer       Date:  2011-06-20       Impact factor: 6.860

5.  Severe chronic diarrhea and maculopapular rash: a case report.

Authors:  Alessandra Elvevi; Federica Grifoni; Federica Branchi; Umberto Gianelli; Dario Conte
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

6.  Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors:  Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

7.  Systemic mastocytosis: a rare case of increased liver stiffness.

Authors:  Stefanie Adolf; Gunda Millonig; Helmut Karl Seitz; Andreas Reiter; Peter Schirmacher; Thomas Longerich; Sebastian Mueller
Journal:  Case Reports Hepatol       Date:  2012-10-11

Review 8.  Bone fragility in patients affected by congenital diseases non skeletal in origin.

Authors:  L Masi; S Ferrari; M K Javaid; S Papapoulos; D D Pierroz; M L Brandi
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

9.  Adult mastocytosis: a review of the Santo António Hospital 's experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease.

Authors:  Iolanda Conde Fernandes; Maria dos Anjos Teixeira; Inês Freitas; Manuela Selores; Rosário Alves; Margarida Lima
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

10.  Mast Cell Leukemia with Ascites and Multiple Organs Damage.

Authors:  Elham Jafari; Ali Hadipour; Behjat Kalantari Khandani; Firoozeh Abolhasani
Journal:  Iran J Pathol       Date:  2019-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.